Protesters Demand Affordable Diabetes Treatment and Better Access to Insulin in South Africa

Diabetes, a chronic condition affecting millions globally, is increasingly becoming a focal point for healthcare advocacy, particularly in low and middle-income countries. In South Africa, a recent protest highlighted the challenges faced by those living with diabetes, particularly regarding the cost and accessibility of insulin. Organized by advocacy groups such as Médecins Sans Frontières (MSF) and T1 International, the demonstration took place outside the Johannesburg office of pharmaceutical giant Novo Nordisk. Protesters voiced concerns over the rising costs of diabetes treatment and the limited access to affordable insulin, particularly following Novo Nordisk’s decision to phase out human insulin pens in favor of more expensive analogue alternatives.

Rising Costs and Limited Access to Insulin

For millions of South Africans living with diabetes, access to insulin is a daily necessity, and affordability is crucial. Insulin pens, which provide a more precise and convenient method of administration compared to traditional syringes, are being gradually phased out by Novo Nordisk, one of the world’s leading producers of diabetes medications. Instead, the company is focusing on manufacturing more profitable analogue insulin and new diabetes treatments like GLP-1 receptor agonists. This shift is significant, as analogue insulin is more expensive and often inaccessible in low-resource settings.

The pharmaceutical industry’s emphasis on newer medications has drawn criticism for creating disparities in diabetes care. In wealthy countries, most diabetes patients have transitioned to modern or analogue insulin, which allows for better blood sugar management. In contrast, human insulin, the traditional form, remains more commonly used in low and middle-income countries due to its affordability. The discontinuation of human insulin pens raises concerns over how diabetic patients in these regions will manage their condition, especially those who rely on the convenience of pen devices.

Impact of Pharmaceutical Decisions in South Africa

Novo Nordisk’s decision to phase out human insulin pens sparked protests in Johannesburg. According to MSF, several hundred people gathered to express their frustration over the increasing difficulty in obtaining affordable insulin. Protesters highlighted that switching to vials and syringes would not only be inconvenient but could also lead to dosage errors, increasing the risks for individuals managing diabetes. The protest underscored a broader issue within the pharmaceutical industry—the prioritization of profit over accessibility.

Global diabetes advocacy groups, including MSF, have repeatedly called on pharmaceutical corporations like Novo Nordisk, Eli Lilly, and Sanofi to reduce prices and increase access to diabetes medications. Despite the profitability of newer medications like GLP-1 receptor agonists, which are sold at a significant markup in high-income countries, access to these treatments remains limited in low and middle-income regions. In South Africa, a single insulin pen can cost as much as R51.25, while GLP-1 medicines can reach a staggering R1,979.32 per month—a cost far beyond the reach of many.

A Call for Global Equity in Diabetes Treatment

The advocacy groups argue that pharmaceutical companies must take responsibility for ensuring equitable access to essential medications. In the case of Novo Nordisk, the focus on producing analogue insulin pens for wealthier markets, while phasing out human insulin pens used in poorer regions, has led to accusations of creating a double standard in diabetes care. While analogue insulin may offer superior blood sugar control, its high cost remains prohibitive for many living in low-income settings, where human insulin has been a mainstay for decades.

The issue of diabetes treatment affordability is not confined to South Africa. Globally, 537 million people live with diabetes, and the number is rising rapidly, particularly in low and middle-income countries. In Africa, the number of diabetes cases is expected to increase by 134% by 2045, amplifying the need for accessible and affordable treatment options. Despite this growing demand, companies like Novo Nordisk continue to prioritize markets with higher profit margins, leaving millions without adequate access to life-saving insulin.

The Role of Governments and International Organizations

To address these disparities, organizations like MSF are urging governments and international bodies to intervene. They advocate for pharmaceutical companies to reduce prices, allow generic manufacturers to produce insulin, and ensure a consistent supply chain for all regions. This call echoes the broader movement for global health equity, emphasizing that no individual should be denied access to essential medications due to financial barriers.

Furthermore, the recent U.S. Senate hearing on the pricing practices of companies like Novo Nordisk reflects a growing international scrutiny over pharmaceutical profiteering. Lawmakers and advocacy groups are questioning why life-saving drugs, which cost relatively little to produce, are sold at exorbitant prices. The disparity in access to insulin, particularly between high-income and low-income countries, underscores the need for a fairer and more transparent pricing model within the pharmaceutical industry.

The Path Forward: Ensuring Access for All

As the global diabetes crisis intensifies, the call for equitable access to treatment is louder than ever. In South Africa and beyond, the shift away from affordable human insulin pens highlights the urgent need for pharmaceutical companies to balance profit with responsibility. The recent protests in Johannesburg serve as a reminder that access to essential medications should not be a privilege reserved for the wealthy but a right available to all.

To achieve this, advocacy groups, governments, and international health organizations must work together to pressure pharmaceutical giants into making diabetes treatment affordable and accessible to everyone, regardless of economic status. Until then, the fight for affordable diabetes care continues, with millions of lives hanging in the balance. Keep posted for further updates.